Lakewood-Amedex Biotherapeutics, Inc. LABT

LABT Company Overview

Lakewood-Amedex Biotherapeutics, Inc. (OTC: LABT) is a biotechnology company focused on the development of antimicrobial and anti-biofilm therapeutics intended to address drug-resistant infections and other unmet medical needs. The company has historically operated in the biopharmaceutical sector, with research efforts centered on synthetic peptide and peptide-mimetic technologies designed to combat bacterial pathogens, fungal infections, and biofilm-related complications. Public disclosures indicate that LABT has pursued applications in medical devices, wound care, and infectious disease therapeutics.

The company’s principal scientific platform has been associated with its Bisphosphocin Nu-3 technology family, which was developed to target microbial biofilms and resistant organisms. LABT evolved through the merger of Lakewood Ventures and Amedex, Inc., combining public market access with Amedex’s antimicrobial peptide research portfolio. Available public filings and market disclosures indicate that the company has remained in an early-stage development phase, with limited or no recurring commercial revenue reported in recent periods. Data regarding current commercialization scale and active product sales is inconclusive based on available public sources.